Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India

Chidambharam Choccalingam, Lakshmi Rao, Sruti Rao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims of the study were to evaluate the expression Cytokeratin 5/6(CK5/6) and Epidermal Growth Factor Receptor (EGFR) among triple negative breast cancers and high grade infiltrating duct carcinomas. Further to probe if triple negative phenotype can be a surrogate marker for basal phenotype and to correlate the expression of basal markers with disease free survivals among triple negative phenotype and high grade infiltrating duct carcinomas. Methods: Expression of CK5/6 and EGFR were studied by Immunohistochemistry (IHC) in 31 triple negative and 19 non-triple negative high grade breast carcinomas. Results: 21 of the 31 triple negative phenotype (67.7%) breast carcinomas and 7 out of 19 non-triple negative (36.8%) breast carcinomas showed expression of basal markers (CK5/6 and/or over-expression of EGFR). There were statistically significant associations of all the basal-like tumors with negative hormonal status. The basal markers positive phenotype subjects had a shorter disease free interval as compared to basal markers negative phenotype subjects. Conclusion: Basal-like breast carcinomas constitute a unique clinical and pathological entity, characterized by high tumor grade and a propensity for lack of ER, PR and HER2 expression. Basal phenotypes have a more aggressive course than non-basal phenotype. "Triple negative" status cannot be used as a surrogate for "basal marker expression".

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalBreast Cancer: Basic and Clinical Research
Volume6
Issue number1
DOIs
Publication statusPublished - 01-01-2012
Externally publishedYes

Fingerprint

Keratin-6
Keratin-5
Rural Hospitals
Epidermal Growth Factor Receptor
Tertiary Care Centers
India
Breast Neoplasms
Phenotype
Carcinoma, Ductal, Breast
Biomarkers
Triple Negative Breast Neoplasms
Disease-Free Survival
Neoplasms
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{fb3037a1ccb542b18a71c33928767ebb,
title = "Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India",
abstract = "Aims of the study were to evaluate the expression Cytokeratin 5/6(CK5/6) and Epidermal Growth Factor Receptor (EGFR) among triple negative breast cancers and high grade infiltrating duct carcinomas. Further to probe if triple negative phenotype can be a surrogate marker for basal phenotype and to correlate the expression of basal markers with disease free survivals among triple negative phenotype and high grade infiltrating duct carcinomas. Methods: Expression of CK5/6 and EGFR were studied by Immunohistochemistry (IHC) in 31 triple negative and 19 non-triple negative high grade breast carcinomas. Results: 21 of the 31 triple negative phenotype (67.7{\%}) breast carcinomas and 7 out of 19 non-triple negative (36.8{\%}) breast carcinomas showed expression of basal markers (CK5/6 and/or over-expression of EGFR). There were statistically significant associations of all the basal-like tumors with negative hormonal status. The basal markers positive phenotype subjects had a shorter disease free interval as compared to basal markers negative phenotype subjects. Conclusion: Basal-like breast carcinomas constitute a unique clinical and pathological entity, characterized by high tumor grade and a propensity for lack of ER, PR and HER2 expression. Basal phenotypes have a more aggressive course than non-basal phenotype. {"}Triple negative{"} status cannot be used as a surrogate for {"}basal marker expression{"}.",
author = "Chidambharam Choccalingam and Lakshmi Rao and Sruti Rao",
year = "2012",
month = "1",
day = "1",
doi = "10.4137/BCBCR.S8611",
language = "English",
volume = "6",
pages = "21--29",
journal = "Breast Cancer: Basic and Clinical Research",
issn = "1178-2234",
publisher = "Libertas Academica Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India

AU - Choccalingam, Chidambharam

AU - Rao, Lakshmi

AU - Rao, Sruti

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Aims of the study were to evaluate the expression Cytokeratin 5/6(CK5/6) and Epidermal Growth Factor Receptor (EGFR) among triple negative breast cancers and high grade infiltrating duct carcinomas. Further to probe if triple negative phenotype can be a surrogate marker for basal phenotype and to correlate the expression of basal markers with disease free survivals among triple negative phenotype and high grade infiltrating duct carcinomas. Methods: Expression of CK5/6 and EGFR were studied by Immunohistochemistry (IHC) in 31 triple negative and 19 non-triple negative high grade breast carcinomas. Results: 21 of the 31 triple negative phenotype (67.7%) breast carcinomas and 7 out of 19 non-triple negative (36.8%) breast carcinomas showed expression of basal markers (CK5/6 and/or over-expression of EGFR). There were statistically significant associations of all the basal-like tumors with negative hormonal status. The basal markers positive phenotype subjects had a shorter disease free interval as compared to basal markers negative phenotype subjects. Conclusion: Basal-like breast carcinomas constitute a unique clinical and pathological entity, characterized by high tumor grade and a propensity for lack of ER, PR and HER2 expression. Basal phenotypes have a more aggressive course than non-basal phenotype. "Triple negative" status cannot be used as a surrogate for "basal marker expression".

AB - Aims of the study were to evaluate the expression Cytokeratin 5/6(CK5/6) and Epidermal Growth Factor Receptor (EGFR) among triple negative breast cancers and high grade infiltrating duct carcinomas. Further to probe if triple negative phenotype can be a surrogate marker for basal phenotype and to correlate the expression of basal markers with disease free survivals among triple negative phenotype and high grade infiltrating duct carcinomas. Methods: Expression of CK5/6 and EGFR were studied by Immunohistochemistry (IHC) in 31 triple negative and 19 non-triple negative high grade breast carcinomas. Results: 21 of the 31 triple negative phenotype (67.7%) breast carcinomas and 7 out of 19 non-triple negative (36.8%) breast carcinomas showed expression of basal markers (CK5/6 and/or over-expression of EGFR). There were statistically significant associations of all the basal-like tumors with negative hormonal status. The basal markers positive phenotype subjects had a shorter disease free interval as compared to basal markers negative phenotype subjects. Conclusion: Basal-like breast carcinomas constitute a unique clinical and pathological entity, characterized by high tumor grade and a propensity for lack of ER, PR and HER2 expression. Basal phenotypes have a more aggressive course than non-basal phenotype. "Triple negative" status cannot be used as a surrogate for "basal marker expression".

UR - http://www.scopus.com/inward/record.url?scp=84856778273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856778273&partnerID=8YFLogxK

U2 - 10.4137/BCBCR.S8611

DO - 10.4137/BCBCR.S8611

M3 - Article

AN - SCOPUS:84856778273

VL - 6

SP - 21

EP - 29

JO - Breast Cancer: Basic and Clinical Research

JF - Breast Cancer: Basic and Clinical Research

SN - 1178-2234

IS - 1

ER -